Dose-Escalation Results of 225Ac-J591 Plus 177Lu-PSMA-I&T
Scott Tagawa, MD, MS, FACP, and fellow researchers carried out a phase 1/2 trial investigating the combination of 225Ac-J591 with 177Lu-PSMA-I&T (aka PNT2002). The study’s results will be presented at the American Society of Clinical Oncology 2023 Annual Meeting. Eligible patients had progressive metastatic castration-resistant prostate cancer (mCRPC), 2 or more prior androgen receptor pathway inhibitors, prior chemotherapy (or unfit/refuse), and 1 or more lesions with a standardized uptake value greater than liver uptake. ...

Latest News

Editorial Advisory Board

Expert Interviews

Knowledge Hubs

Curated clinical content based on conditions, therapies, and technologies

Prostate Cancer
Prostate Cancer

The Uromigos

Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD

Conference Coverage

Live meeting highlights

Emily MenendezASCO 2023 | June 3, 2023
Results from the CHAARTED trial demonstrated that ADT and docetaxel improves OS and QOL at 12 months compared with ADT alone.
Read More
Zachary BessetteASCO 2023 | June 2, 2023
A post hoc analysis of the IMvigor130 trial examined OS outcomes during first-line induction for patients with mUC.
Zachary BessetteASCO 2023 | June 2, 2023
64Cu-SAR-bisPSMA may be safe and effective for detecting PSMA-expressing lesions, and 200MBq may be the optimal dose.
Emily MenendezASCO 2023 | June 1, 2023
An observational study sought to determine variation in recurrence after TURBT between sites taking part in the RESECT study.

Video Insights

Clinical discussions with experts in the field